153 related articles for article (PubMed ID: 11479431)
1. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo.
Bosserhoff AK; Echtenacher B; Hein R; Buettner R
Melanoma Res; 2001 Aug; 11(4):417-21. PubMed ID: 11479431
[TBL] [Abstract][Full Text] [Related]
2. Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration.
Winklmeier A; Contreras-Shannon V; Arndt S; Melle C; Bosserhoff AK
Cancer Sci; 2009 Feb; 100(2):261-8. PubMed ID: 19200257
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo.
Guba M; Bosserhoff AK; Steinbauer M; Abels C; Anthuber M; Buettner R; Jauch KW
Br J Cancer; 2000 Nov; 83(9):1216-22. PubMed ID: 11027436
[TBL] [Abstract][Full Text] [Related]
4. [MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma].
Bosserhoff AK; Golob M; Buettner R; Landthaler M; Hein R
Hautarzt; 1998 Oct; 49(10):762-9. PubMed ID: 9857251
[TBL] [Abstract][Full Text] [Related]
5. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
[TBL] [Abstract][Full Text] [Related]
6. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity.
Bosserhoff AK; Stoll R; Sleeman JP; Bataille F; Buettner R; Holak TA
Lab Invest; 2003 Nov; 83(11):1583-94. PubMed ID: 14615412
[TBL] [Abstract][Full Text] [Related]
7. Melanoma inhibitory activity promotes melanoma development through activation of YBX1.
Schmid R; Meyer K; Spang R; Schittek B; Bosserhoff AK
Pigment Cell Melanoma Res; 2013 Sep; 26(5):685-96. PubMed ID: 23672612
[TBL] [Abstract][Full Text] [Related]
8. Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression.
Bosserhoff AK
Pigment Cell Res; 2005 Dec; 18(6):411-6. PubMed ID: 16280006
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes.
Tatzel J; Poser I; Schroeder J; Bosserhoff AK
Pigment Cell Res; 2005 Apr; 18(2):92-101. PubMed ID: 15760338
[TBL] [Abstract][Full Text] [Related]
10. p54nrb is a new regulator of progression of malignant melanoma.
Schiffner S; Zimara N; Schmid R; Bosserhoff AK
Carcinogenesis; 2011 Aug; 32(8):1176-82. PubMed ID: 21642354
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
[TBL] [Abstract][Full Text] [Related]
12. Processing of MIA protein during melanoma cell migration.
Schmidt J; Bosserhoff AK
Int J Cancer; 2009 Oct; 125(7):1587-94. PubMed ID: 19521988
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-derived soluble factor enhances melanoma inhibitory activity expression by uveal melanoma cells in vitro.
Callejo SA; Marshall JC; Cools-Lartigue J; Saraiva VS; Burnier MN
Melanoma Res; 2004 Apr; 14(2):91-5. PubMed ID: 15057037
[TBL] [Abstract][Full Text] [Related]
14. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
[TBL] [Abstract][Full Text] [Related]
15. Expression, function and clinical relevance of MIA (melanoma inhibitory activity).
Bosserhoff AK; Buettner R
Histol Histopathol; 2002 Jan; 17(1):289-300. PubMed ID: 11813878
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques.
Jachimczak P; Apfel R; Bosserhoff AK; Fabel K; Hau P; Tschertner I; Wise P; Schlingensiepen KH; Schuler-Thurner B; Bogdahn U
Int J Cancer; 2005 Jan; 113(1):88-92. PubMed ID: 15386421
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP) [corrected].
Hau P; Wise P; Bosserhoff AK; Blesch A; Jachimczak P; Tschertner I; Bogdahn U; Apfel R
J Invest Dermatol; 2002 Sep; 119(3):562-9. PubMed ID: 12230496
[TBL] [Abstract][Full Text] [Related]
18. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
19. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
20. Functional role of MIA in melanocytes and early development of melanoma.
Poser I; Tatzel J; Kuphal S; Bosserhoff AK
Oncogene; 2004 Aug; 23(36):6115-24. PubMed ID: 15208686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
